Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone

Supportive Care in Cancer

Volumn 17, Issue 9, 2009, Pages 1177-1185

  Johnson, Brendan ^a   Adams, Laurel ^a   Lu, Emily ^a   Zhang, Ke ^a,c   Lebowitz, Peter ^a   Lates, Christian ^b   Blum, Robert ^b  

^a GLAXOSMITHKLINE   (United States)

^b Buffalo Clinical Research Center   (United States)

^c PFIZER INC   (United States)

Author keywords

Casopitant; CINV; Dexamethasone; Ondansetron

Indexed keywords

CASOPITANT; DEXAMETHASONE; ONDANSETRON;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD SAMPLING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISORIENTATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DYSPEPSIA; FATIGUE; FEMALE; HICCUP; HUMAN; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NORMAL HUMAN; PARESTHESIA; PRIORITY JOURNAL; RHINOPHARYNGITIS; SYNCOPE; TACHYCARDIA; UPPER ABDOMINAL PAIN;

ADOLESCENT; ADULT; ANTIEMETICS; DEXAMETHASONE; DRUG THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; ONDANSETRON; PIPERAZINES; PIPERIDINES; RECEPTORS, NEUROKININ-1; VOMITING; YOUNG ADULT;

EID: 68949208670     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-008-0571-5     Document Type: Article

References (26)

1. Adams L, Johnson B, Zhang K, Yue L, Kirby L, Lebowitz P, Stoltz R (J Support Care Cancer, companion paper) Minimal impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron doi: 10.1007/s00520-008-0572-4
2. W Arpornwirat I Albert VL Hansen et al. 2006 Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC) J Clin Oncol 24 8512
3. Z Aziz W Arpornwirat J Herrstedt et al. 2008 Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC) J Clin Oncol 26 20512
4. L Cohen CA de Moor P Eisenberg et al. 2007 Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings Support Care Cancer 15 497 503
5. PH De Mulder C Seynaeve JB Vermorken et al. 1990 Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study Ann Intern Med 113 834 840
6. CM Dixon PV Colthup CJ Serabjit-Singh et al. 1995 Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans Drug Metab Dispos 23 1225 1230
7. DM Gentile ES Tomlinson JL Maggs et al. 1996 Dexamethasone metabolism by human liver in vitro metabolite identification. and inhibition of 6-hydroxylation J Pharmacol Exp Ther 277 105 112
8. S Grunberg Z Aziz A Shaharyan et al. 2008 Phase III results of a novel neurokinin-1 (NK-1) receptor antagonist, casopitant: single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC) J Clin Oncol 26 9540
9. SM Grunberg RR Deuson P Mavros et al. 2004 Incidence of chemotherapy-induced nausea and emesis after modern antiemetics Cancer 100 2261 2268
10. SM Grunberg D Osoba PJ Hesketh et al. 2005 Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update Support Care Cancer 13 80 84
11. J Herrstedt S Grunberg J Rolski et al. 2008 Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC) J Clin Oncol 26 9549
12. PJ Hesketh MG Kris SM Grunberg et al. 1997 Proposal for classifying the acute emetogenicity of cancer chemotherapy J Clin Oncol 15 103 109
13. Hesketh PJ (2004) Management of nausea and vomiting in cancer and cancer treatment. Jones & Bartlett Publishers, Boston
14. JK Lamba YS Lin EG Schuetz et al. 2002 Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Deliv Rev 54 1271 1294
15. CT Liau NM Chu HE Liu et al. 2005 Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes Support Care Cancer 13 277 286
16. D Loew O Schuster EH Graul 1986 Dose-dependent pharmacokinetics of dexamethasone Eur J Clin Pharmacol 30 225 230
17. M Marty P Pouillart S Scholl et al. 1990 Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis N Engl J Med 322 816 821
18. JS McCune RL Hawke EL LeCluyse et al. 2000 In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone Clin Pharmacol Ther 68 356 366
19. Multinational Association of Supportive Care in Cancer (2008) Antiemetic subcommittee guidelines. http://www.mascc.org
20. National Comprehensive Cancer Network Clinical practice guidelines in oncology. http://www.NCCN.org
21. N Neymark R Crott 2005 Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials Support Care Cancer 13 812 818
22. F Roila PJ Hesketh J Herrstedt 2006 Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia international antiemetic consensus conference Ann Oncol 17 20 28
23. FM Schnell 2003 Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control Oncologist 8 187 198
24. J Strausz J Rolski Z Aziz et al. 2008 Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC) J Clin Oncol 26 20586
25. CC Sun DC Bodurka CB Weaver et al. 2005 Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer Support Care Cancer 13 219 227
26. DG Warr PJ Hesketh RJ Gralla et al. 2005 Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy J Clin Oncol 23 2822 2830